Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis

Ocular Immunology and Inflammation
Timothy L Comstock, Heleen H Decory

Abstract

To compare the efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) and dexamethasone 0.1%/tobramycin 0.3% (DM/T) ophthalmic suspensions in reducing select signs of blepharitis. Data were pooled from two studies (one from the USA; one from China) of adults (n = 627) with blepharokeratoconjunctivitis treated with LE/T or DM/T four times daily for 2 weeks (safety population). Efficacy analyses included 495 eyes (247 LE/T, 248 DM/T) with any baseline sign of blepharitis. At Day 15, the least squares mean change from baseline in composite blepharitis severity was similar between LE/T (-2.86) and DM/T (-2.99) (90% CI for mean treatment difference: -0.35, 0.11). Intraocular pressure (IOP) increases ≥10 mmHg over baseline were reported for 1 US patient (DM/T group) and 19 Chinese patients (6 LE/T; 13 DM/T). LE/T was similarly effective in reducing the signs of blepharitis compared with DM/T, but demonstrated a better safety profile with respect to changes in IOP.

References

Dec 1, 1966·American Journal of Ophthalmology·S M PodosW R Morton
Jan 1, 1993·Journal of Ocular Pharmacology·J D BartlettJ F Howes
Aug 26, 1998·Journal of Glaucoma·G D NovackM B Sherwood
Oct 24, 2001·The British Journal of Ophthalmology·V A ParkerN J Sarkies
Oct 1, 1963·Archives of Ophthalmology·B BECKER, D W MILLS
Aug 25, 2004·Investigative Ophthalmology & Visual Science·Claude KaufmannMichael A Thiel
Nov 22, 2005·The British Journal of Ophthalmology·A KotechaD F Garway-Heath
Sep 4, 2007·American Journal of Ophthalmology·Dhananjay ShuklaRamaswami Krishnadas
Dec 21, 2007·Acta Ophthalmologica·Gauti JóhannessonChristina Lindén
Apr 23, 2009·The Ocular Surface·Michael A Lemp, Kelly K Nichols
Feb 1, 2011·Ophthalmology·Arie Y NemetIgor Kaiserman
Mar 23, 2011·Journal of Cataract and Refractive Surgery·David F ChangYorghos Tripodis
Apr 27, 2012·International Journal of Inflammation·Timothy L Comstock, Heleen H Decory
May 18, 2012·The Cochrane Database of Systematic Reviews·Kristina LindsleyEsen K Akpek
Dec 13, 2012·Journal of Cataract and Refractive Surgery·Stephen S Lane, Edward J Holland
Aug 21, 2013·Ophthalmology·Ge WenUNKNOWN Multi-Ethnic Pediatric Eye Disease Study Group
Dec 19, 2013·PloS One·David Y ChiangFred A Pereira
Jan 5, 2014·PloS One·Chun-Chi ChiangFung-Chang Sung
May 20, 2014·Survey of Ophthalmology·Hyun-Kyung Cho, Changwon Kee
Oct 7, 2014·The Ocular Surface·Stephen C PflugfelderVictor L Perez
Jan 3, 2015·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Onsiri ThanathaneeOlan Suwan-apichon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.